# Mario Sznol

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mario-sznol/

## Facts

| Field | Value |
| --- | --- |
| Citations | 69,474 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 92 |
| i10-index | 250 |
| Last Known Institution | Yale Cancer Center |
| OpenAlex ID | https://openalex.org/A5007198397 |
| ORCID iD | https://orcid.org/0000-0002-4359-8749 |
| Works | 532 |

## Researcher papers

- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed/)
- [Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma](https://scholariq.org/papers/clinical-activity-and-molecular-correlates-of-response-to-atezolizumab-alone-or/)
- [Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/overall-survival-and-long-term-safety-of-nivolumab-anti-programmed-death-1/)
- [Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy](https://scholariq.org/papers/bempegaldesleukin-selectively-depletes-intratumoral-tregs-and-potentiates-t-cell/)
- [Interferon-stimulated neutrophils as a predictor of immunotherapy response](https://scholariq.org/papers/interferon-stimulated-neutrophils-as-a-predictor-of-immunotherapy-response/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Researcher university

- [Yale Cancer Center](https://scholariq.org/institutions/yale-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.